A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)

M. Gounder, P. Schöffski, V. Villalobos, G. Cote, R. Chugh, T. W.W. Chen, T. Jahan, E. T. Loggers, A. Italiano, A. Gupta, M. Agulnik, S. Attia, R. L. Jones, B. A. van Tine, G. D.D. Demetri, M. Roche, I. Sapir, S. Daigle, A. Clawson, S. Stacchiotti

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)viii581-viii582
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Gounder, M., Schöffski, P., Villalobos, V., Cote, G., Chugh, R., Chen, T. W. W., Jahan, T., Loggers, E. T., Italiano, A., Gupta, A., Agulnik, M., Attia, S., Jones, R. L., van Tine, B. A., Demetri, G. D. D., Roche, M., Sapir, I., Daigle, S., Clawson, A., & Stacchiotti, S. (2018). A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii581-viii582. https://doi.org/10.1093/annonc/mdy299.014